Alexander E. Perl, MD, MS

Alexander E. Perl, MD, MS, associate professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the challenges of using immunotherapy with antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), and CAR T-cell therapies in acute myeloid leukemia (AML). 

Currently, the main ADC that is being used in clinical practice is gemtuzumab ozogamicin (Mylotarg), which is approved for the treatment of adult patients with newly diagnosed CD33-positive AML, says Perl. However, other potential agents are in early development and are being used exclusively in clinical trials, adds Perl. 

Specifically, bispecific antibodies are showing promise in this space; however, questions regarding optimal targets, payload, and drug delivery still need to be answered. 

CAR T-cell therapy has shown success in acute lymphoblastic leukemia (ALL), but are much harder to create in AML. The myeloid blasts, the tumor cells in AML, are shared with normally-occurring hematopoietic elements in healthy cells, Perl explains. An agent that effectively kills those cells may result in increased extramedullary or marrow toxicity against normal cells that you might wish to preserve, concludes Perl.

Videos

Alexander E. Perl, MD, MS, discusses the challenges of using immunotherapy with antibody-drug conjugates, bispecific T-cell engagers, and CAR T-cell therapies in acute myeloid leukemia. 
 

Dr. Perl on Challenges of Implementing Immunotherapy in AML

Alexander E. Perl, MD, MS, associate professor of medicine, University of Pennsylvania, Perelman School of Medicine, discusses how to assess what therapy is best for patients with acute myeloid leukemia (AML). 

In the past, AML treatment was largely a one-size-fits-all approach. Patient fitness was the only criteria that was used to determine whether to administer induction 7+3 chemotherapy, low-intensity treatment with low-dose cytarabine or hypomethylating agent, or supportive care for patients who could not tolerate either therapy. 

Today, the genetic composition of the leukemia is used to determine the optimal therapy. Fitness still plays a role in determining whether a patient should receive intensive or low-intensity treatment. Notably, induction strategies that are personalized to the genetic makeup of the disease result in improved survival, says Perl. 

Personalized approaches confer improved survival across subtypes of AML, adds Perl, including therapy-related AML, myelodysplastic syndrome-related AML, 

-mutant AML, and core-binding factor AML. 

Alexander E. Perl, MD, MS, discusses how to assess what therapy is best for patients with acute myeloid leukemia. 
 

Author | Alexander E. Perl, MD, MS

Articles

Dr. Perl on Challenges of Implementing Immunotherapy in AML

Dr. Perl on Choosing the Optimal Therapy in AML